Advertisement
Screener

Lantern Pharma Inc. (LTRN) Deferred Offering Costs

2.8 / 5 stars · 68/120 Roast Me

Lantern Pharma Inc. Deferred Offering Costs

Lantern Pharma Inc. (LTRN) had Deferred Offering Costs of $55.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-14.

Financial Statements › Balance Sheet › Assets › Assets, Current

us-gaap:DeferredOfferingCosts · last filed 2026-08-14

  • 2026-06-30: Deferred Offering Costs $55.00K.
  • 2026-03-31: Deferred Offering Costs $55.00K.
  • 2025-12-31: Deferred Offering Costs $88.00K.
  • 2021-03-31: Deferred Offering Costs $0.00.
Period endDeferred Offering Costs
2026-06-30$55.00K
10-Q · filed 2026-08-14
2026-03-31$55.00K
10-Q · filed 2026-05-15
2025-12-31$88.00K
10-Q · filed 2026-08-14
2021-03-31$0.00
10-Q · filed 2021-05-03
2020-12-31$101.20K
10-K · filed 2021-03-10
2020-09-30$0.00
10-Q · filed 2020-10-29
2019-12-31$191.00K
10-K · filed 2021-03-10

Similar stocks

Stock NameCountryMarket CapPE Ratio
Citius Pharmaceuticals, Inc. (CTXR)United States$0.016B-133.06
Anebulo Pharmaceuticals, Inc. (ANEB)United States$0.015B
Korsana Biosciences, Inc. (CYCN)United States$0.016B
ACTUATE THERAPEUTICS, INC. (ACTU)United States$0.015B
Tvardi Therapeutics, Inc. (TVRD)United States$0.014B
Vyome Holdings, Inc (HIND)United States$0.014B-1.38
BullFrog AI Holdings, Inc. (BFRG)United States$0.014B
Pasithea Therapeutics Corp. (KTTA)United States$0.017B-0.81
Allarity Therapeutics, Inc. (ALLR)United States$0.017B-1.66
LISATA THERAPEUTICS, INC. (LSTA)United States$0.014B-2.13